sodium tetradecyl sulfate 1 mg.
The Fibro-Vein preparation has a venosclerosing effect and has surface-active properties.
When the drug is injected into the lumen of a varicose vein, irritation of the intima of the vessel occurs, followed by fibrosis, adhesion of the vein walls and its obliteration.
It does not have a noticeable effect on the functions of the central and peripheral nervous system, cardiovascular system, kidney and liver function, biochemical parameters of blood and urine.
When injected into perivascular tissues, it is irritating.
- Treatment of uncomplicated, moderately severe varicose veins of the lower extremities by the method of compression sclerotherapy.
- Treatment of telangiectasias.
Application during pregnancy and lactation
Fibro-Vein is contraindicated in pregnancy and lactation.
- Hypersensitivity to Fibro-Vein;
- severe liver and kidney disease;
- acute thrombosis and thrombophlebitis;
- soft tissue infection;
- infectious diseases;
- obliterating peripheral arteriosclerosis;
- diabetic angiopathy;
- pregnancy and lactation;
- after alcoholism treatment;
- taking oral contraceptives;
- sedentary lifestyle;
- varicose veins, as a result of tumors of the abdominal cavity and small pelvis;
- heart defects requiring surgery;
- extensive and pronounced varicose veins (including deep ones) with valve insufficiency; phlebosclerosis;
- toxic hyperthyroidism;
- oncological diseases;
- acute infections;
- violation of the cellular composition of the blood;
- acute respiratory or skin diseases;
- general diseases requiring adherence to bed rest, heart disease with symptoms of decompensation.
Local reactions: possible skin hyperemia, slight pain or burning sensation at the injection site.
Allergic reactions: rare.
Pharmaceutically incompatible with heparin. It is not recommended to combine with oral contraceptives (especially antiovulatory).
How to take, course and dosage
Fibro-Vein is injected intravenously into the lumen of an isolated segment of an empty superficial vein with immediate prolonged compression (application of a compression bandage).
The dosage is determined depending on the size of the vein to be hardened; the usual dose is 1 ml (no more) in one place.
For Fibro-Wayne 1% is the maximum single dose up to 10 ml. If necessary, additional injections are performed after a 2-week break.
1. Fibro-Vein should be used by physicians familiar with the technique of sclerotherapy. Valve insufficiency and deep vein condition must be properly assessed.
2. Sclerotherapy of veins is carried out with caution with absolute confidence in the patency of deep and communicative veins of the lower extremities.
3. Before starting treatment, it is necessary to know the patient's allergic history. You can enter the patient with 0.25-0.5 ml of Fibro-Vein 24 hours before the start of treatment to identify a possible allergic reaction.
4. Care must be taken when treating patients with peripheral atherosclerosis, Buerger's disease.
5. Especially carefully it is necessary to inject the drug into the area above and behind the medial ankle, because there is the posterior tibial artery.
6. Avoid extravasal (paravenous) and intra-arterial administration.
7. Do not use the drug in case of precipitation or color change of the solution.
8. When the temperature drops in the solution, a precipitate may form, which dissolves upon heating.
9. For the prevention of relapse after treatment, patients are advised to wear elastic stockings.
Aqueous solution for injection.